Idarubicin Hexal (Idarubicin Hydrochloride)

• Idarubicin is an anthracycline used in the management of acute myeloid leukemia and related disease states.
• Acute Myeloid Leukemia (de novo): induces remission in newly diagnosed patients
• Relapsed Acute Myeloid Leukemia: provides a therapeutic option after prior treatment failure
• High‑Risk Acute Myeloid Leukemia: used as part of consolidation therapy to reduce relapse risk

• Idarubicin intercalates between DNA base pairs, disrupting the double‑helix structure and inhibiting the enzyme topoisomerase II. This inhibition prevents the relegation of DNA strands during replication, leading to accumulation of double‑strand breaks. Additionally, the drug generates free radicals that cause oxidative damage to cellular membranes and proteins, collectively resulting in cytotoxicity of rapidly proliferating malignant cells. The effect is dose‑dependent and contributes to the antineoplastic activity observed in clinical settings.

Idarubicin may cause a range of adverse reactions, varying from frequent to rare but serious.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported
• Alopecia: hair loss due to effects on rapidly dividing cells
• Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia
• Mucositis: inflammation of the mouth and gastrointestinal lining

Serious or Rare Side Effects

• Cardiotoxicity: irreversible heart muscle damage that may lead to heart failure
• Severe neutropenic infection: life‑threatening bacterial or fungal infections due to profound neutropenia
• Secondary malignancies: increased risk of developing new cancers after treatment

When using Idarubicin, several precautions should be observed to minimize risks and ensure safe administration.

• Cardiac monitoring: baseline and periodic echocardiograms are recommended due to risk of cardiotoxicity.
• Hematologic assessment: complete blood counts should be performed regularly to detect myelosuppression.
• Liver function evaluation: hepatic impairment may alter drug clearance, requiring dose consideration.
• Avoid concurrent anthracyclines: cumulative exposure increases risk of cardiac and marrow toxicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicin interacts with several agents; awareness of these interactions helps prevent enhanced toxicity or reduced efficacy.

Major Interactions (Avoid)

• Other anthracyclines: additive cardiotoxicity and marrow suppression.
• Cyclophosphamide: synergistic myelosuppression may be severe.
• Radiation therapy: combined treatment can increase tissue damage and fibrosis.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): CYP3A4 inhibition may raise Idarubicin plasma levels.
• Warfarin: altered anticoagulant effect requiring INR monitoring.
• Loop diuretics (e.g., furosemide): may exacerbate electrolyte disturbances and affect cardiac function.